Applications of Gene Therapy for Biomedical Engineering

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Biomedical Engineering and Biomaterials".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 214

Special Issue Editor

Memorial Sloan Kettering Cancer Center, New York, NY, USA
Interests: congenital scoliosis; congenital anomalies of the kidney and urinary tract; age-related macular degeneration; retinal degeneration; CRISPR editing

Special Issue Information

Dear Colleagues,

An impending breakthrough in healthcare lies at the intersection of retinal degeneration and gene therapy. This transformative approach aims to harness the potential of genetic interventions to address the challenges posed by retinal degenerative disorders. The objective is to develop targeted biological therapies, employing gene-based substitutes or interventions in vitro to replace or restore compromised retinal function in vivo due to degeneration. While the promise of gene therapy for retinal degeneration is evident, there exists both an immediate and long-term need to overcome the intricate engineering and life science challenges inherent in translating these advances to tangible benefits in human healthcare. This requires a focus on the development of bioprocess technology, which is essential for seamlessly transferring the laboratory-based practices of gene therapy and genetic interventions to clinical applications. This forthcoming Special Issue of Bioengineering, "Applications of Gene Therapy for Biomedical Engineering", addresses this critical need by consolidating insights from global experts in gene therapy, retinal biology, and bioprocess engineering. Together, these contributions present significant advances in the engineering sciences, driving the successful implementation of gene-based therapies for retinal degeneration and paving the way for transformative breakthroughs in ocular healthcare.

Dr. Nan Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • retinal degeneration
  • gene therapy
  • targeted biological therapies

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop